Ken Griffin Iovance Biotherapeutics, Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$7.28 - $11.9 $115,752 - $189,210	15,900 Added 5.1%	327,600 $3.08 Million
Q2 2024 Aug 14, 2024	SELL	$7.78 - $14.19 $2.31 Million - $4.22 Million	-297,500 Reduced 48.83%	311,700 $2.5 Million
Q1 2024 May 15, 2024	BUY	$7.59 - $17.47 $2.04 Million - $4.7 Million	268,900 Added 79.02%	609,200 $9.03 Million
Q4 2023 Feb 14, 2024	SELL	$3.3 - $8.89 $41,580 - $112,014	-12,600 Reduced 3.57%	340,300 $2.77 Million
Q3 2023 Nov 14, 2023	BUY	$4.44 - $8.79 $263,736 - $522,125	59,400 Added 20.24%	352,900 $1.61 Million
Q2 2023 Aug 14, 2023	SELL	$5.36 - $9.06 $165,624 - $279,954	-30,900 Reduced 9.53%	293,500 $2.07 Million
Q1 2023 May 15, 2023	BUY	$5.53 - $8.22 $841,666 - $1.25 Million	152,200 Added 88.39%	324,400 $1.98 Million
Q4 2022 Feb 14, 2023	SELL	$5.62 - $10.0 $189,956 - $338,000	-33,800 Reduced 16.41%	172,200 $1.1 Million
Q3 2022 Nov 14, 2022	SELL	$9.53 - $13.11 $669,959 - $921,633	-70,300 Reduced 25.44%	206,000 $1.97 Million

314

241M

3.77M

1.7M

Ticker IOVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 157,800,992
Market Cap $1.44B
Description
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.